| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 944 | 1,244 | 1,432 | 1,290 | 1,252 | 1,509 | 1,672 | 1,507 | 1,276 | 1,342 | 1,889 | 1,765 | 1,521 | 1,686 | 1,943 | 1,934 | 1,882 | 1,867 | 2,296 | 2,210 | 2,077 | 2,047 | 2,398 | 2,415 | 2,238 | 2,778 | 2,842 | 2,673 | 2,504 | 2,628 | 3,130 | 3,086 | 2,971 | 3,034 | 3,503 | 3,418 | 3,024 | 3,152 | 3,549 | 3,467 |
| Expenses | 777 | 1,001 | 1,127 | 1,052 | 993 | 1,210 | 1,328 | 1,214 | 1,102 | 1,218 | 1,405 | 1,381 | 1,389 | 1,455 | 1,555 | 1,613 | 1,619 | 1,585 | 1,811 | 1,729 | 1,746 | 1,470 | 1,762 | 1,789 | 1,901 | 2,139 | 2,176 | 2,121 | 2,162 | 2,373 | 2,626 | 2,442 | 2,652 | 2,579 | 2,751 | 2,668 | 2,546 | 2,423 | 2,662 | 2,615 |
| EBITDA | 167 | 242 | 306 | 238 | 260 | 299 | 344 | 294 | 174 | 124 | 485 | 384 | 132 | 231 | 388 | 321 | 263 | 282 | 484 | 481 | 331 | 577 | 636 | 626 | 337 | 640 | 666 | 552 | 343 | 255 | 505 | 644 | 319 | 455 | 752 | 750 | 478 | 729 | 887 | 852 |
| Operating Profit % | 13 % | 16 % | 17 % | 17 % | 14 % | 18 % | 19 % | 18 % | 12 % | 7 % | 24 % | 21 % | 7 % | 12 % | 19 % | 16 % | 13 % | 14 % | 20 % | 21 % | 15 % | 26 % | 25 % | 23 % | 13 % | 22 % | 22 % | 19 % | 13 % | 8 % | 15 % | 20 % | 9 % | 13 % | 20 % | 20 % | 13 % | 20 % | 22 % | 23 % |
| Depreciation | 18 | 21 | 26 | 23 | 24 | 23 | 26 | 26 | 26 | 31 | 35 | 38 | 40 | 43 | 46 | 48 | 57 | 56 | 56 | 60 | 81 | 67 | 70 | 69 | 69 | 71 | 73 | 78 | 83 | 76 | 77 | 78 | 78 | 72 | 74 | 70 | 83 | 81 | 79 | 85 |
| Interest | 17 | 23 | 20 | 19 | 10 | 10 | 12 | 12 | 11 | 13 | 18 | 15 | 10 | 16 | 16 | 15 | 7 | 16 | 18 | 17 | 14 | 17 | 18 | 13 | 11 | 13 | 12 | 11 | 17 | 27 | 25 | 27 | 29 | 30 | 30 | 26 | 27 | 29 | 28 | 36 |
| Profit Before Tax | 150 | 211 | 280 | 213 | 225 | 266 | 307 | 255 | 136 | 81 | 432 | 332 | 81 | 172 | 326 | 258 | 199 | 210 | 410 | 405 | 235 | 493 | 548 | 543 | 258 | 556 | 582 | 464 | 243 | 152 | 402 | 539 | 212 | 353 | 648 | 655 | 367 | 619 | 780 | 731 |
| Tax | 19 | 7 | 8 | 23 | 139 | 23 | 19 | 19 | -1 | 17 | 105 | 152 | 15 | 35 | 66 | 53 | 28 | 23 | 29 | 15 | 44 | 70 | 66 | 80 | 9 | 76 | 23 | -69 | 135 | 20 | 55 | 79 | 144 | 65 | 33 | 51 | 63 | 69 | 78 | 90 |
| Net Profit | 132 | 204 | 272 | 190 | 87 | 243 | 288 | 236 | 137 | 64 | 327 | 181 | 66 | 137 | 260 | 205 | 171 | 187 | 381 | 390 | 192 | 423 | 482 | 464 | 249 | 480 | 559 | 533 | 108 | 131 | 348 | 460 | 68 | 288 | 615 | 604 | 305 | 550 | 702 | 641 |
| EPS in ₹ | 11.00 | 16.82 | 22.32 | 15.63 | 7.25 | 19.97 | 23.65 | 19.52 | 11.46 | 5.99 | 26.82 | 14.36 | 5.61 | 11.39 | 21.28 | 16.94 | 14.00 | 15.51 | 31.02 | 31.95 | 15.79 | 35.30 | 39.48 | 37.72 | 20.07 | 39.15 | 45.52 | 43.96 | 9.00 | 10.68 | 27.67 | 38.03 | 5.94 | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 |
Alkem Laboratories
5,033.20
-19.35
(-0.38%)
There are new updates from the company1 day ago
View
Market Cap
60,410.80 Cr
EPS
150.19
PE Ratio
27.78
Dividend Yield
0.80 %
Industry
Healthcare52 Week High
6,439.90
52 Week Low
4,407.05
PB Ratio
5.23
Debt to Equity
0.15
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from17 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
9.84 %
Net Income Growth
79.93 %
Cash Flow Change
15.78 %
ROE
58.48 %
ROCE
31.25 %
EBITDA Margin (Avg.)
27.51 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 5,296 | 5,535 | 6,568 | 7,666 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 |
| Fixed Assets | 1,374 | 1,450 | 1,797 | 2,284 | 2,530 | 2,908 | 2,793 | 2,902 | 2,683 | 2,873 |
| Current Assets | 2,338 | 2,769 | 2,917 | 4,013 | 4,216 | 5,506 | 6,923 | 8,435 | 8,730 | 10,412 |
| Capital Work in Progress | 111 | 172 | 299 | 381 | 493 | 363 | 393 | 340 | 323 | 159 |
| Investments | 61 | 509 | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 484 |
| Other Assets | 3,750 | 3,404 | 3,919 | 4,557 | 4,861 | 6,413 | 8,000 | 10,457 | 10,129 | 12,060 |
| Total Liabilities | 5,296 | 5,535 | 6,568 | 7,666 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 |
| Current Liabilities | 2,006 | 1,538 | 1,690 | 2,383 | 2,218 | 3,245 | 3,604 | 4,805 | 3,707 | 3,995 |
| Non Current Liabilities | 205 | 210 | 296 | 297 | 419 | 392 | 357 | 417 | 615 | 866 |
| Total Equity | 3,085 | 3,787 | 4,583 | 4,985 | 5,572 | 6,309 | 7,558 | 8,847 | 9,435 | 10,714 |
| Reserve & Surplus | 2,975 | 3,668 | 4,444 | 4,840 | 5,415 | 6,137 | 7,353 | 8,614 | 9,021 | 10,288 |
| Share Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 39 | 3 | 40 | 0 | 82 | -73 | -2 | 58 | 42 | -208 |
| Investing Activities | -235 | 205 | -294 | -351 | -318 | -737 | -995 | -1,433 | 120 | -1,011 |
| Operating Activities | 326 | 726 | 471 | 266 | 780 | 585 | 1,265 | 1,111 | 1,683 | 1,948 |
| Financing Activities | -52 | -927 | -138 | 85 | -379 | 79 | -272 | 380 | -1,761 | -1,145 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 60.16 % | 58.84 % | 58.84 % | 57.13 % | 57.13 % | 57.14 % | 57.16 % | 57.16 % | 57.16 % | 57.16 % | 56.74 % | 56.74 % | 56.74 % | 56.38 % | 55.66 % | 55.66 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.11 % | 8.69 % | 9.02 % | 10.15 % |
| DIIs | 12.97 % | 14.28 % | 13.78 % | 13.76 % | 13.93 % | 13.88 % | 15.26 % | 16.44 % | 16.69 % | 15.43 % | 17.64 % | 14.94 % | 15.63 % | 18.57 % | 19.21 % | 18.01 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 21.75 % | 21.70 % | 21.15 % | 22.85 % | 22.63 % | 22.33 % | 22.28 % | 21.74 % | 21.44 % | 20.61 % | 19.36 % | 18.60 % | 18.31 % | 16.15 % | 15.84 % | 15.90 % |
| Others | 5.12 % | 5.17 % | 6.23 % | 6.26 % | 6.31 % | 6.65 % | 5.30 % | 4.67 % | 4.71 % | 6.80 % | 6.26 % | 9.72 % | 0.21 % | 0.21 % | 0.26 % | 0.28 % |
| No of Share Holders | 92,594 | 93,540 | 87,392 | 86,881 | 81,869 | 84,104 | 79,721 | 76,516 | 73,440 | 66,790 | 69,442 | 65,184 | 65,830 | 69,627 | 74,744 | 84,038 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 15 | 13 | 16 | 25 | 30 | 34 | 50 | 40 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.75 | 0.74 | 0.69 | 0.9 | 0.83 | 1.03 | 1.01 | 0.79 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Change in Management
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Dislcosure letter under Regulation 11(5) of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011.
Dislcosure letter under Regulation 11(5) of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Newspaper Publication
Results- Financial Results For Quarter Ended Dec 31 2024
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Acquisition
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Investor Presentation
Corporate Action-Board approves Dividend
Results- Financials Results For Quarter Ended Dec 31 2024
Board Meeting Outcome for Outcome Of The Board Meeting Dated 07/02/2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement Under Regulation 30 Of SEBI LODR- Regulatory Order
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Corporate Action - Fixes Record Date For Interim Dividend
Corporate Action-Board to consider Dividend
Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited.
Technical Indicators
RSI(14)
Neutral 62.25
ATR(14)
Volatile 130.55
STOCH(9,6)
Overbought 88.30
STOCH RSI(14)
Overbought 97.98
MACD(12,26)
Bullish 54.40
ADX(14)
Weak Trend 20.57
UO(9)
Bearish 65.55
ROC(12)
Uptrend But Slowing Down 6.05
WillR(14)
Overbought -11.38
About Alkem Laboratories
Alkem Laboratories Limited is an Indian pharmaceutical company headquartered in Mumbai, with global operations. The company develops, manufactures, and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. It has a portfolio of over 800 brands in India and operates in more than 40 international markets, with the United States as its key focus. Alkem is ranked the fifth largest pharmaceutical company in India by domestic sales. The company's product offerings span various therapeutic areas such as anti-infective, cardiology, neurology, and gastroenterology. Alkem has invested in research and development, filing numerous Abbreviated New Drug Applications (ANDAs) with the US FDA. The company has multiple manufacturing facilities in India and abroad, and has expanded through acquisitions and subsidiaries in different countries.
Listing Date
23 Dec, 2015(9 Years,
31 days)
Website
Chairperson NameBasudeo N Singh
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
